Table 1 Demographics.
Characteristics | Pharmacometabolomics study (n = 59) | Retrospective study (n = 130) |
|---|---|---|
Median age, yr (range) | 12.3 (1.3–22.2) | 9.5 (0.6–22.2) |
Gender, No. (%) | ||
Male | 35 (59.3) | 69 (53.1) |
Female | 24 (40.7) | 61 (46.9) |
Diagnosis, No. (%) | ||
Acute leukaemia | 40 (67.8) | 92 (70.8) |
Acute lymphoblastic leukaemia | 20 (33.9) | 41 (31.5) |
Acute myeloid leukaemia | 17 (28.8) | 44 (33.8) |
Other | 3 (5.1) | 7 (5.4) |
Lymphoma | 2 (3.4) | 3 (2.3) |
Haematological disease | 4 (6.8) | 11 (8.5) |
Myelodysplastic syndrome | 1 (1.7) | 3 (2.3) |
Haemophagocytic lymphohistiocytosis | 1 (1.7) | 3 (2.3) |
Severe aplastic anaemia | 1 (1.7) | 1 (0.7) |
Paroxysmal nocturnal haemoglobinuria | 1 (1.7) | 1 (0.7) |
Solid tumour | 7 (11.9) | 11 (8.5) |
Immunodeficiency | 4 (6.8) | 9 (6.9) |
Other diseases* | 2 (3.4) | 4 (3.1) |
Conditioning regimen, No. (%) | ||
Busulfan fludarabine etoposide | 19 (32.2) | 58 (44.6) |
Busulfan fludarabine | 18 (30.5) | 52 (40.0) |
Busulfan fludarabine melphalan | 6 (10.2) | 6 (4.6) |
Busulfan melphalan | 6 (10.2) | 10 (7.7) |
Other | 0 (0.0) | 4 (3.1) |
